RESUMO
Social and neurobiological factors independently associate with the development of antisocial behavior during adolescence, yet it is unclear how these factors contribute to antisocial behavior in girls. Using a longitudinal sample of 45 adolescent girls (age in years at scan: M = 15.38, SD = 0.33), this study examined the contributions of parent-adolescent relationship quality and deviant peer affiliation from 6th-8th grades along with the neural correlates of risk taking in 9th grade to later antisocial behavior. High parent-adolescent closeness in early adolescence predicted lower antisocial behavior for girls in later adolescence via lower affiliation with deviant peer groups and less activation of the medial prefrontal cortex during risk taking. Findings highlight the enduring role of parents and peers during adolescence, and the importance of investigating social relationships alongside the brain to identify a holistic understanding of the development of antisocial behavior in girls.
Assuntos
Comportamento do Adolescente , Transtorno da Personalidade Antissocial , Feminino , Humanos , Adolescente , Pais , Grupo Associado , Assunção de Riscos , Estudos LongitudinaisRESUMO
A disbelief in alibis is one contributor to wrongful convictions. One reason that triers-of-fact may disbelieve alibis is that they lack evidence to corroborate the whereabouts of the suspect at the time of the crime. Contextual factors, such as when the alibi was disclosed and what was the nature of the crime, can also affect alibi believability. This paper outlines two studies where mock jurors evaluated an investigation and trial description online and rated alibi believability, defendant character trait ratings, and verdicts. Both studies examined the impact of corroborative alibi evidence and the timing of the alibi disclosure. In addition, Study 1 included the type of crime and Study 2 included the number of alibi corroborators as additional independent variables. We hypothesized that alibis would be viewed more positively when they were disclosed earlier rather than later, were corroborated by strong physical evidence and multiple corroborators, and involved less violent offenses. As hypothesized, in both studies, alibis with strong physical evidence were thought to be more believable than those with no physical evidence but the number of corroborators and type of crime did not affect any dependent measures. Delayed timing had some negative effects on views of the defendant's character. Corroborative physical evidence affected alibi believability consistently, and contextual factors mattered less. Both implications and suggestions for future research are further discussed.
Assuntos
Crime , Tomada de Decisões , Adulto , Feminino , Humanos , Masculino , Sugestão , Revelação da VerdadeRESUMO
The kidney is a complex excretory organ playing a crucial role in various physiological processes such as fluid and electrolyte balance, control of blood pressure, removal of waste products, and drug disposition. Drug-induced kidney injury (DIKI) remains a significant cause of candidate drug attrition during drug development. However, the incidence of renal toxicities in preclinical studies is low, and the mechanisms by which drugs induce kidney injury are still poorly understood. Although some in vitro investigational tools have been developed, the in vivo assessment of renal function remains the most widely used methodology to identify DIKI. Stand-alone safety pharmacology studies usually include assessment of glomerular and hemodynamic function, coupled with urine and plasma analyses. However, as renal function is not part of the ICH S7A core battery, such studies are not routinely conducted by pharmaceutical companies. The most common approach consists in integrating renal/urinary measurements in repeat-dose toxicity studies. In addition to the standard analyses and histopathological examination of kidneys, novel promising urinary biomarkers have emerged over the last decade, offering greater sensitivity and specificity than traditional renal parameters. Seven of these biomarkers have been qualified by regulatory agencies for use in rat toxicity studies.
Assuntos
Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos/métodos , Rim/efeitos dos fármacos , Animais , Biomarcadores , Controle de Medicamentos e Entorpecentes , Humanos , Rim/anatomia & histologia , Rim/fisiologiaRESUMO
In 2012, AstraZeneca entered into a strategic relationship with Charles River Laboratories whereby preclinical safety packages comprising safety pharmacology, toxicology, formulation analysis, in vivo ADME, bioanalysis and pharmacokinetics studies are outsourced. New processes were put in place to ensure seamless workflows with the aim of accelerating the delivery of new medicines to patients. Here, we describe in more detail the AstraZeneca preclinical safety outsourcing model and the way in which a collaborative tool has helped to translate the processes in AstraZeneca and Charles River Laboratories into simpler integrated workflows that are efficient and visible across the two companies.
Assuntos
Avaliação Pré-Clínica de Medicamentos , Indústria Farmacêutica/organização & administração , Laboratórios/organização & administração , Serviços Terceirizados , Comportamento Cooperativo , Eficiência Organizacional , Modelos OrganizacionaisRESUMO
Tumors frequently display a glycolytic phenotype with increased flux through glycolysis and concomitant synthesis of lactate. To maintain glycolytic flux and prevent intracellular acidification, tumors efflux lactate via lactate transporters (MCT1-4). Inhibitors of lactate transport have the potential to inhibit glycolysis and tumor growth. We developed a small molecule inhibitor of MCT1 (AZD3965) and assessed its activity across a panel of cell lines. We explored its antitumor activity as monotherapy and in combination with doxorubicin or rituximab. AZD3965 is a potent inhibitor of MCT1 with activity against MCT2 but selectivity over MCT3 and MCT4. In vitro, AZD3965 inhibited the growth of a range of cell lines especially haematological cells. Inhibition of MCT1 by AZD3965 inhibited lactate efflux and resulted in accumulation of glycolytic intermediates. In vivo, AZD3965 caused lactate accumulation in the Raji Burkitt's lymphoma model and significant tumor growth inhibition. Moreover, AZD3965 can be combined with doxorubicin or rituximab, components of the R-CHOP standard-of-care in DLBCL and Burkitt's lymphoma. Finally, combining lactate transport inhibition by AZD3965 with GLS1 inhibition in vitro, enhanced cell growth inhibition and cell death compared to monotherapy treatment. The ability to combine AZD3965 with novel, and standard-of-care inhibitors offers novel combination opportunities in haematological cancers.
RESUMO
INTRODUCTION: With the recent development of more sensitive biomarkers to assess kidney injury preclinically, a survey was designed i) to investigate what strategies are used to investigate renal toxicity in both ICH S7A compliant Safety Pharmacology (SP) studies after a single dose of a compound and within repeat-dose toxicity studies by large pharmaceutical companies today; ii) to understand whether renal SP studies have impact or utility in drug development and/or if it may be more appropriate to assess renal effects after multiple doses of compounds; iii) to ascertain how much mechanistic work is performed by the top 15 largest pharmaceutical companies (as determined by R&D revenue size); iv) to gain an insight into the impact of the validation of DIKI biomarkers and their introduction in the safety evaluation paradigm; and v) to understand the impact of renal/urinary safety study data on progression of projects. METHODS: Two short anonymous surveys were submitted to SP leaders of the top 15 pharmaceutical companies, as defined by 2012 R&D portfolio size. Fourteen multiple choice questions were designed to explore the strategies used to investigate renal effects in both ICH S7A compliant SP studies and within toxicology studies. RESULTS: A 67% and 60% response rate was obtained in the first and second surveys, respectively. Nine out of ten respondent companies conduct renal excretory measurements (eg. urine analysis) in toxicology studies whereas only five out of ten conduct specific renal SP studies; and all of those 5 also conduct the renal excretory measurements in toxicology studies. These companies measure and/or calculate a variety of parameters as part of these studies, and also on a case by case basis include regulatory qualified and non-qualified DIKI biomarkers. Finally, only one company has used renal/urinary functional data alone to stop a project, whereas the majority of respondents combine renal data with other target organ assessments to form an integrated decision-making set. CONCLUSION: These short surveys highlighted areas of similarity: a) urinary measurements are most commonly taken on repeat-dose toxicity studies, and b) renal SP studies are less often utilised. The two major differences are a) lack of consistent use of DIKI biomarkers in urinary safety studies and b) the way large pharmaceutical companies assess renal function. Finally, suggestions were made to improve the safety assessment methods for determining the safety of compounds with potential renal liability.
Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Indústria Farmacêutica/métodos , Nefropatias/induzido quimicamente , Animais , Biomarcadores/metabolismo , Desenho de Fármacos , Indústria Farmacêutica/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Inquéritos e Questionários , Testes de Toxicidade/métodosRESUMO
INTRODUCTION: Parts A and B of the ICH S7 guidelines on safety pharmacology describe the in vivo studies that must be conducted prior to first time in man administration of any new pharmaceutical. ICH S7A requires a consideration of the sensitivity and reproducibility of the test systems used. This could encompass maintaining a dataset of historical pre-dose values, power analyses, as well as a demonstration of acceptable model sensitivity and robust pharmacological validation. During the process of outsourcing safety pharmacology studies to Charles River Laboratories, AstraZeneca set out to ensure that models were performed identically in each facility and saw this as an opportunity to review the inter-laboratory variability of these essential models. METHODS: The five in vivo studies outsourced were the conscious dog telemetry model for cardiovascular assessment, the rat whole body plethysmography model for respiratory assessment, the rat modified Irwin screen for central nervous system assessment, the rat charcoal meal study for gastrointestinal assessment and the rat metabolic cage study for assessment of renal function. Each study was validated with known reference compounds and data were compared across facilities. Statistical power was also calculated for each model. RESULTS: The results obtained indicated that each of the studies could be performed with comparable statistical power and could achieve a similar outcome, independent of facility. DISCUSSION: The consistency of results obtained from these models across multiple facilities was high thus providing confidence that the models can be run in different facilities and maintain compliance with ICH S7A and B.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Modelos Biológicos , Testes de Toxicidade/métodos , Animais , Cães , Desenho de Fármacos , Controle de Medicamentos e Entorpecentes , Guias como Assunto , Humanos , Cooperação Internacional , Masculino , Pletismografia Total/métodos , Ratos , Ratos Wistar , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Telemetria/métodos , Testes de Toxicidade/normasRESUMO
Current immunosuppressive therapies act on T lymphocytes by modulation of cytokine production, modulation of signaling pathways or by inhibition of the enzymes of nucleotide biosynthesis. We have identified a previously unknown series of immunomodulatory compounds that potently inhibit human and rat T lymphocyte proliferation in vitro and in vivo in immune-mediated animal models of disease, acting by a novel mechanism. Here we identify the target of these compounds, the monocarboxylate transporter MCT1 (SLC16A1), using a strategy of photoaffinity labeling and proteomic characterization. We show that inhibition of MCT1 during T lymphocyte activation results in selective and profound inhibition of the extremely rapid phase of T cell division essential for an effective immune response. MCT1 activity, however, is not required for many stages of lymphocyte activation, such as cytokine production, or for most normal physiological functions. By pursuing a chemistry-led target identification strategy, we have discovered that MCT1 is a previously unknown target for immunosuppressive therapy and have uncovered an unsuspected role for MCT1 in immune biology.